Dyadic International (DYAI) Stock Price

Dyadic International Price

NASDAQ·CLOSED
0.95USD-0.17 (-16.18 %)
Market closed

Revenue at Dyadic International has contracted by 12.4% per year over the past 19 years to 1.23 M USD. Earnings per share have grown at 51.5% per year over the last 6 years. Dyadic International's net margin stands at -597.6%, down from -543.7% several years earlier. Analysts set a median price target of 7.14 USD, implying 651.4% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.

Dyadic International stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Dyadic International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Dyadic International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Dyadic International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Dyadic International Stock Price History
DateDyadic International Price
8/5/20260.95 USD
8/4/20261.12 USD
8/3/20261.06 USD
7/31/20261.05 USD
7/30/20261.07 USD
7/29/20261.09 USD
7/27/20261.17 USD
7/23/20261.21 USD
7/22/20261.30 USD
7/21/20261.47 USD
7/20/20261.21 USD
7/17/20261.26 USD
7/16/20261.19 USD
7/15/20261.22 USD
7/14/20261.21 USD
7/13/20261.00 USD
7/10/20261.06 USD
7/9/20261.07 USD
7/8/20261.00 USD
7/7/20261.06 USD
7/6/20260.96 USD
7/2/20260.94 USD
7/1/20261.02 USD
6/30/20260.90 USD
6/29/20260.88 USD
6/26/20260.80 USD
6/25/20260.74 USD
6/24/20260.73 USD
6/23/20260.81 USD
6/22/20260.79 USD
6/18/20260.78 USD
6/17/20260.85 USD
6/16/20260.78 USD
6/15/20260.80 USD
6/12/20260.68 USD
6/11/20260.68 USD
6/10/20260.73 USD
6/9/20260.68 USD
6/8/20260.70 USD
6/5/20260.71 USD
6/4/20260.72 USD
6/3/20260.70 USD
6/2/20260.69 USD
6/1/20260.78 USD
5/29/20260.81 USD
5/28/20260.71 USD
5/27/20260.76 USD
5/26/20260.76 USD
5/22/20260.76 USD
5/21/20260.74 USD
5/20/20260.74 USD
5/19/20260.72 USD
5/18/20260.72 USD
5/15/20260.72 USD
5/14/20260.69 USD
5/13/20260.71 USD
5/12/20260.72 USD
5/11/20260.72 USD
5/8/20260.77 USD
5/7/20260.75 USD
5/6/20260.76 USD
5/5/20260.77 USD
5/4/20260.75 USD
4/22/20260.83 USD
4/21/20260.84 USD
4/20/20260.88 USD
4/17/20260.88 USD
4/16/20260.88 USD
4/15/20260.88 USD
4/14/20260.87 USD
4/13/20260.86 USD
4/10/20260.89 USD
4/9/20260.88 USD
4/8/20260.89 USD
4/7/20260.88 USD
4/6/20260.87 USD
4/2/20260.89 USD
4/1/20260.85 USD
3/31/20260.82 USD
3/30/20260.73 USD
3/27/20260.68 USD
3/26/20260.70 USD
3/25/20260.87 USD
3/24/20260.84 USD
3/23/20260.86 USD
3/20/20260.94 USD
3/19/20260.80 USD
3/18/20260.78 USD
3/17/20260.80 USD
3/16/20260.81 USD
3/13/20260.76 USD
3/12/20260.76 USD
3/11/20260.80 USD
3/10/20260.83 USD
3/9/20260.80 USD
3/6/20260.77 USD
3/5/20260.76 USD
3/4/20260.82 USD
3/3/20260.79 USD
3/2/20260.77 USD
2/27/20260.78 USD
2/26/20260.78 USD
2/25/20260.84 USD
2/24/20260.82 USD
2/23/20260.80 USD
2/20/20260.80 USD
2/19/20260.80 USD
2/18/20260.81 USD
2/17/20260.81 USD
2/13/20260.83 USD
2/12/20260.83 USD
2/11/20260.80 USD
2/10/20260.83 USD
2/9/20260.83 USD
2/6/20260.85 USD
2/5/20260.85 USD
2/4/20260.85 USD
2/3/20260.85 USD
2/2/20260.86 USD
1/30/20260.87 USD
1/29/20260.91 USD
1/28/20260.88 USD
1/27/20260.88 USD
1/26/20260.88 USD
1/23/20260.90 USD
1/22/20260.91 USD
1/21/20260.89 USD
1/20/20260.89 USD
1/16/20260.87 USD
1/15/20260.89 USD
1/14/20260.88 USD
1/13/20260.87 USD
1/12/20260.93 USD
1/9/20260.95 USD
1/8/20260.97 USD
1/7/20260.97 USD
1/6/20260.93 USD
1/5/20260.91 USD
1/2/20260.94 USD
12/31/20250.94 USD
12/30/20250.88 USD
12/29/20250.89 USD
12/26/20250.95 USD
12/24/20250.98 USD
12/23/20250.99 USD
12/22/20251.00 USD
12/19/20251.00 USD
12/18/20250.91 USD
12/17/20250.90 USD
12/16/20250.91 USD
12/15/20250.83 USD
12/12/20250.91 USD
12/11/20250.92 USD
12/10/20250.99 USD
12/9/20251.00 USD
12/8/20250.99 USD
12/5/20250.95 USD
12/4/20251.00 USD
12/3/20250.94 USD
12/2/20250.91 USD
12/1/20250.93 USD
11/28/20250.95 USD
11/26/20250.94 USD
11/25/20250.95 USD
11/24/20250.91 USD
11/21/20250.92 USD
11/20/20250.93 USD
11/19/20250.93 USD
11/18/20250.90 USD
11/17/20250.89 USD
11/14/20250.91 USD
11/13/20250.91 USD
11/12/20250.94 USD
11/11/20250.98 USD
11/10/20251.00 USD
11/7/20250.93 USD
11/6/20250.98 USD
11/5/20251.04 USD
11/4/20251.05 USD
11/3/20251.08 USD
10/31/20251.13 USD
10/30/20251.17 USD
10/29/20251.10 USD
10/28/20251.13 USD
10/27/20251.18 USD
10/24/20251.14 USD
10/23/20251.18 USD
10/22/20251.10 USD
10/21/20251.11 USD
10/20/20251.13 USD
10/17/20251.07 USD
10/16/20251.05 USD
10/15/20251.03 USD
10/14/20251.05 USD
10/13/20251.07 USD
10/10/20251.05 USD
10/9/20251.13 USD
10/8/20251.13 USD
10/7/20251.14 USD
10/6/20251.18 USD
10/3/20251.16 USD
10/2/20251.22 USD
10/1/20251.30 USD
9/30/20251.18 USD
9/29/20251.17 USD
9/26/20251.10 USD
9/25/20251.17 USD
9/24/20251.15 USD
9/23/20251.08 USD
9/22/20251.03 USD
9/19/20251.07 USD
9/18/20250.98 USD
9/17/20251.00 USD
9/16/20250.99 USD
9/15/20250.97 USD
9/12/20250.97 USD
9/11/20250.99 USD
9/10/20250.98 USD
9/9/20250.98 USD
9/8/20250.97 USD
9/5/20250.91 USD
9/4/20250.96 USD
9/3/20250.98 USD
9/2/20250.95 USD
8/29/20250.92 USD
8/28/20250.91 USD
8/27/20250.93 USD
8/26/20250.90 USD
8/25/20250.87 USD
8/22/20250.85 USD
8/21/20250.78 USD
8/20/20250.81 USD
8/19/20250.79 USD
8/18/20250.80 USD
8/15/20250.75 USD
8/14/20250.80 USD
8/13/20250.82 USD
8/12/20250.85 USD
8/11/20250.81 USD
8/8/20250.94 USD
8/7/20250.95 USD
8/6/20250.99 USD
Access this data via the Eulerpool API
Get Free API Key

Dyadic International Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
2.93 M USD
-10.17 M USD
-9.74 M USD
Jan 1, 2023
2.90 M USD
-8.23 M USD
-6.80 M USD
Jan 1, 2024
3.50 M USD
-5.90 M USD
-5.81 M USD
Jan 1, 2025
1.23 M USD
-7.15 M USD
-7.36 M USD
Jan 1, 2026 (e)
6.82 M USD
-6.82 M USD
-2.93 M USD
Jan 1, 2027 (e)
13.08 M USD
-13.08 M USD
1.32 M USD
Jan 1, 2028 (e)
11.00 M USD
-11.00 M USD
-293,181.00 USD
Jan 1, 2029 (e)
19.74 M USD
-19.74 M USD
7.04 M USD

Dyadic International Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 12:00 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
12.00–––1.001.001.002.002.002.003.001.006.0013.0011.0019.00
-29.41––––––100.00––50.00-66.67500.00116.67-15.3872.73
33.33–––-100.00-100.00-100.00-50.00-50.00-50.0066.67-100.00-100.00-100.00-100.00-100.00
4.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.002.00-1.00-6.00-13.00-11.00-19.00
-5.00-3.00-5.00-7.00-7.00-9.00-10.00-14.00-10.00-8.00-5.00-7.00-6.00-13.00-11.00-19.00
-41.67–––-700.00-900.00-1,000.00-700.00-500.00-400.00-166.67-700.00-100.00-100.00-100.00-100.00
-5.0065.00-3.00-2.00-5.00-8.00-9.00-13.00-9.00-6.00-5.00-7.00-2.001.00–7.00
–-1,400.00-104.62-33.33150.0060.0012.5044.44-30.77-33.33-16.6740.00-71.43-150.00––
34.1134.2536.1928.7126.7127.4527.4828.0828.5628.8129.3232.6232.6232.6232.6232.62
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Dyadic International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Dyadic International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Dyadic International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Dyadic International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Dyadic International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Dyadic International stock margins

The Dyadic International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dyadic International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dyadic International.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
19.11 %
-612.67 %
-543.73 %
Jan 1, 2022
27.54 %
-346.92 %
-332.23 %
Jan 1, 2023
31.84 %
-283.90 %
-234.42 %
Jan 1, 2024
65.82 %
-168.82 %
-166.19 %
Jan 1, 2025
-88.25 %
-579.88 %
-597.63 %
Jan 1, 2026 (e)
-88.25 %
-100.00 %
-43.00 %
Jan 1, 2027 (e)
-88.25 %
-100.00 %
10.08 %
Jan 1, 2028 (e)
-88.25 %
-100.00 %
-2.67 %

Dyadic International Stock Revenue, EBIT, Earnings per Share

The Dyadic International earnings per share therefore indicates how much revenue Dyadic International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.09 USD
-0.52 USD
-0.47 USD
Jan 1, 2022
0.10 USD
-0.36 USD
-0.34 USD
Jan 1, 2023
0.10 USD
-0.29 USD
-0.24 USD
Jan 1, 2024
0.12 USD
-0.20 USD
-0.20 USD
Jan 1, 2025
0.04 USD
-0.22 USD
-0.23 USD
Jan 1, 2026 (e)
0.23 USD
-0.21 USD
-0.10 USD
Jan 1, 2027 (e)
0.45 USD
-0.40 USD
0.05 USD
Jan 1, 2028 (e)
0.38 USD
-0.34 USD
-0.01 USD

Dyadic International business model & stock analysis

The company Dyadic International Inc was founded in the Netherlands in 1979 and is now headquartered in Jupiter, Florida. The company is a leading global biotechnology company. Dyadic International specializes in the development and production of enzymes and proteins used in the production of foods, agricultural products, pharmaceuticals, and biopharmaceuticals. The company's business model is based on the use of proprietary technologies and know-how to optimize the production process of enzymes and proteins. Dyadic uses a platform technology called C1, which is based on a mold fungus and allows for the large-scale production of enzymes and proteins. The technology can be used in various ways, providing high flexibility to meet the needs of customers. One of Dyadic's key sectors is the agricultural industry. The company produces enzymes that increase the efficiency of ethanol production and contribute to the reduction of greenhouse gas emissions. Dyadic also works on the development of enzymes that improve the digestibility of animal feed and contribute to the overall health of animals. Another important area is the food industry. Dyadic produces enzymes used in the production of foods such as bread, cheese, beverages, and sweeteners. These enzymes improve product properties, such as shelf life and texture, resulting in higher quality and efficiency in production. Dyadic also operates in the biopharmaceutical industry. The company produces recombinant proteins used in the production of pharmaceuticals. The C1 technology allows for cost-effective production of proteins, particularly beneficial for generic and biosimilar manufacturers. One example of a Dyadic product in the biopharmaceutical industry is the antibody fragment Dyadic rFVIIa, used in the treatment of bleeding in patients with hemophilia. The C1 technology enables the production of the fragment in large quantities and high purity, contributing to cost-effective production. Overall, Dyadic has more than 70 partners and customers from various industries worldwide. The company works closely with its customers to develop and produce tailored solutions for their needs. Through the C1 technology and flexibility in application possibilities, Dyadic International Inc is an important partner for companies in different industries that rely on enzymes and proteins. The main message of the text is that Dyadic International Inc is a leading global biotechnology company specializing in the development and production of enzymes and proteins for various industries.

Dyadic International SWOT Analysis

Strengths

Dyadic International Inc possesses several strengths that contribute to its success in the market. Firstly, the company has a reputation for top-notch research and development capabilities, allowing them to continuously innovate and develop new products. This puts them at the forefront of technological advancements in their industry. Additionally, Dyadic has a strong and experienced management team that provides effective leadership and strategic guidance to the company.

Another significant strength is Dyadic's extensive network of partnerships and collaborations with leading organizations in various industries. This network not only enhances their market reach but also facilitates knowledge sharing and access to valuable resources. Furthermore, the company has a diverse portfolio of intellectual property rights, including patents and trademarks, which provide them with a competitive advantage and protect their innovations.

Weaknesses

Despite its strengths, Dyadic International Inc also faces several weaknesses that pose challenges to its growth and profitability. One notable weakness is the company's dependence on a limited number of key customers. Any significant loss of these customers could have a substantial negative impact on Dyadic's revenue and overall financial performance.

Additionally, Dyadic operates in a highly competitive industry where the barriers to entry are relatively low. This intensifies competition and puts pressure on the company to constantly differentiate itself and innovate to maintain its market position. Moreover, the company's heavy reliance on research and development for product development requires substantial investment, which may strain financial resources.

Opportunities

Despite the challenges, Dyadic International Inc can leverage certain opportunities to enhance its growth prospects. The growing demand for biopharmaceuticals and therapeutic solutions presents a significant opportunity for the company to expand its market presence. By capitalizing on this trend and investing in product development, Dyadic can tap into new revenue streams.

Furthermore, the increasing need for sustainable and environmentally friendly solutions opens doors for Dyadic to leverage its expertise in enzyme technologies. The company can explore collaborations with companies in industries such as biofuels, renewable chemicals, and agriculture to develop innovative and eco-friendly products.

Threats

In addition to opportunities, Dyadic International Inc faces certain threats that could hinder its growth and success. One significant threat is the potential emergence of new competitors with disruptive technologies or alternative solutions. This could lead to increased competition and decreased market share for Dyadic.

Moreover, the company operates in a global market influenced by economic and political uncertainties. Fluctuations in exchange rates, trade policies, and regulatory changes can impact Dyadic's international operations and profitability. Additionally, the legal and regulatory landscape surrounding intellectual property rights can also pose threats if infringements on Dyadic's patents or trademarks occur.

Dyadic International Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dyadic International Employees
Details
Date
Dyadic International Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Dyadic International Segments

Dyadic International Revenue by Segment (1/2)

  • 3 Years

  • Max

Research and Development
Details
Date
Research and Development
Jan 1, 2022
2.68 M USD
Jan 1, 2023
2.55 M USD
Jan 1, 2024
1.61 M USD

Dyadic International Revenue by Segment (2/2)

  • 3 Years

  • Max

License
Details
Date
License
Jan 1, 2022
247,059.00 USD
Jan 1, 2023
352,941.00 USD
Jan 1, 2024
1.89 M USD

Dyadic International Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Other Countries
Details
Date
Other Countries
Jan 1, 2020
123,000.00 USD
Jan 1, 2021
1.72 M USD
Jan 1, 2022
586,000.00 USD
Jan 1, 2023
537,000.00 USD

Dyadic International Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Dyadic International historical P/E ratio, EBIT multiple, and P/S ratio

Dyadic International annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Dyadic International shares outstanding

The number of shares of Dyadic International was 32.62 M in 2025. This indicates how many shares Dyadic International is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
28.08 M Stocks
Jan 1, 2022
28.56 M Stocks
Jan 1, 2023
28.81 M Stocks
Jan 1, 2024
29.32 M Stocks
Jan 1, 2025
32.62 M Stocks
Jan 1, 2026 (e)
32.62 M Stocks
Jan 1, 2027 (e)
32.62 M Stocks
Jan 1, 2028 (e)
32.62 M Stocks

Current Dyadic International forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
7.14
Last Price
0.95
Currency
USD
12M Return Potential
651.42 %
LTM Return
0 %

Dyadic International Analyst Rating Actions

DateFirmActionRating
11/14/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
7/8/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
11/13/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
5/24/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
2/3/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
7/18/2022
Dawson James
Dawson James
DowngradeBuyNeutral
4/5/2022
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
12/17/2021
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy

Dyadic International Earnings Calls

2025

Dyadic International Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/2026-0.04USD-1.01 MUSD-2026 Q2
5/13/2026-0.04USD-918,000.00USD-2026 Q1
3/31/2026-0.05USD-1.37 MUSD-2025 Q4
11/12/2024-0.07USD-1.12 MUSD-2024 Q3
3/27/2024-0.07USD-816,000.00USD-2023 Q4
3/27/2023-0.07USD-3.40 MUSD-2022 Q4
11/10/2022-0.10USD-1.93 MUSD-2022 Q3
8/10/2022-0.09USD-1.87 MUSD-2022 Q2
5/12/2022-0.09USD-2.40 MUSD-2022 Q1
3/29/2022-0.03USD-3.84 MUSD-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the Dyadic International stock

48/100
48
Environment
75
Social
21
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Dyadic International shareholder structure

% Name
16.48356%
Emalfarb (Mark A)
Emalfarb (Mark A)
5.08218%
Apis Capital Advisors LLC
Apis Capital Advisors LLC
3.12080%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.02886%
Chapin Davis Asset Management
Chapin Davis Asset Management
1.17474%
Perkins Capital Management, Inc.
Perkins Capital Management, Inc.
1.11262%
Truist Bank
Truist Bank

Dyadic International Beneficial Ownership Filings (SEC 13D/G)

Free Float
74.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
52.40%
The Pinnacle Fund, L.P.
The Pinnacle Fund, L.P.
SEC ↗
52.40%
David M. Knott
David M. Knott
SEC ↗
52.40%
Barry M. Kitt
Barry M. Kitt
SEC ↗
24.50%
A. Emalfarb
A. Emalfarb
SEC ↗
17.50%
Mark A. Emalfarb
Mark A. Emalfarb
SEC ↗
16.00%
Trust U/A/D February 28, 1996
Trust U/A/D February 28, 1996
SEC ↗
11.58%
Francisco Trust under agreement dated February 28, 1996
Francisco Trust under agreement dated February 28, 1996
SEC ↗
8.60%
36-4518466
36-4518466
SEC ↗
5.80%
52-0556948
52-0556948
SEC ↗
5.60%
JEFFERSON GRAMM
JEFFERSON GRAMM
SEC ↗

Dyadic International Executives and Management Board

7 members · avg. age 62 · 14 % women

ME

Mr. Mark Emalfarb (70)

Chief Executive Officer, Director · since 2004

1.04 M USD

Management

JH

Mr. Joseph Hazelton (49)

President, Chief Operating Officer

478,212.00 USD
RT

Dr. Ronen Tchelet (66)

Vice President - Research and Business Development

423,701.00 USD
PR

Ms. Ping Rawson (48)

Chief Financial Officer

419,127.00 USD

Board of Directors

JK

Mr. Jack Kaye (81)

Independent Director

157,923.00 USD
PL

Mr. Patrick Lucy (57)

Independent Chairman of the Board

152,118.00 USD
SH

Dr. Seth Herbst (66)

Independent Director

126,480.00 USD

Dyadic International Supply Chain

Dyadic International Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#NameTrend
1
Eurofins Scientific
Supplier·Customer·Life Sciences Tools & Services·LU
0.84
0.89
-0.46
0.39
0.71
—
2
Inotiv
Supplier·Customer·Life Sciences Tools & Services·US
0.80
0.85
0.58
0.60
0.28
—
3
Johnson & Johnson
Supplier·Customer·Pharmaceuticals·US
0.66
0.11
-0.87
-0.66
-0.35
—
4
Phibro Animal Health A
Supplier·Customer·Pharmaceuticals·US
0.18
0.57
0.86
0.54
0.15
—

Frequently asked questions about Dyadic International

The main competitors of Dyadic International Inc in the market are companies such as Novozymes A/S, Codexis Inc, and Danisco A/S.

Dyadic International Inc. is a biotechnology company that operates under a unique business model. The company primarily focuses on developing and commercializing innovative enzyme technologies. These enzymes are utilized in various industries such as animal health, biofuels, food and beverages, and industrial applications. With a strong emphasis on research and development, Dyadic International Inc. aims to create sustainable and cost-effective solutions for its customers. By harnessing the power of its proprietary C1 gene expression platform, the company strives to deliver high-performing enzymes that offer numerous benefits in terms of efficiency, environmental sustainability, and overall performance.

Dyadic International Inc is primarily active in the biotechnology industry.

Dyadic International Inc is a biotechnology company founded in 1979 in Jupiter, Florida. The company specializes in developing and producing enzymes and other proteins for various industries, including pharmaceuticals, animal health, and biofuels. With four decades of experience, Dyadic has built a strong reputation for its proprietary C1 gene expression platform, which enables efficient production of biologics at a lower cost. The company has established partnerships with leading organizations worldwide to further advance its technology and product portfolio. Dyadic International Inc continues to strive for innovation and contribute to the biotechnology industry through its cutting-edge research and development efforts.

Dyadic International Inc has achieved several significant milestones. The company successfully developed its proprietary C1 gene expression platform, which is highly efficient in producing biologic vaccines, therapeutic proteins, and other biopharmaceutical products. Dyadic has formed strategic partnerships with leading global companies to utilize the C1 technology in the production of vaccines for COVID-19, potentially addressing the global supply shortage. Additionally, the company has received numerous accolades and recognition for its innovative approach and contributions to the biotechnology industry. Dyadic International Inc continues to make advancements in the field, positioning itself as a key player in the biopharmaceutical sector.

Dyadic International Inc is primarily present in the United States and Europe.

Dyadic International Inc represents a set of core values and corporate philosophy that drive its operations. With a focus on innovation and technological advancements, Dyadic aims to deliver cutting-edge solutions in the field of biotechnology. The company's core values include integrity, collaboration, and a commitment to excellence. By fostering an inclusive and diverse environment, Dyadic emphasizes teamwork and cooperation to achieve its goals. Dyadic International Inc strives to create value for its stakeholders by leveraging its proprietary C1 gene expression system and continuing to advance the biopharmaceutical industry through continuous research and development efforts.

Analysts currently set an average price target of 7.14 USD for the Dyadic International stock (median: 7.14 USD), implying +651.4 % versus the latest price. The consensus is based on 7 analyst ratings.

Dyadic International Analyst Price Targets 2026

7 analysts currently rate the Dyadic International stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Dyadic International to generate revenue of 6.82 M USD and earnings per share of -0.09 USD.

Dyadic International Analyst Price Targets 2026

Converted at the current exchange rate, the Dyadic International share trades at 0.82 EUR (0.95 USD).

The Dyadic International share (DYAI) is listed on 1 stock exchanges, including: NASDAQ (DYAI).

Dyadic International Inc is a company specializing in the development and manufacturing of biotechnological products. The company's business model is based on the use of proprietary technologies and collaboration with partners and customers. The company has three main business areas: 1. Biopharmaceuticals Dyadic has developed a proven platform for the production of proteins and antibodies that can be used in many medical applications. The company is working with various partners on the development of new therapies for diseases such as cancer, autoimmune diseases, and metabolic disorders. 2. Enzymes and cellulose The company also produces enzymes and cellulose-rich products used in the food and paper industries. For example, enzymes are used in the production of foods such as beer, cheese, and bread. The company is also working on finding new applications for the use of cellulose in healthcare and medical products. 3. Research and development Dyadic is also engaged in research and development of new technologies in biotechnology. The company is working on the development of DNA technologies and enzymes that can be applied in various industries. Dyadic also operates a combination of direct sales and partnerships. The company does not have its own marketing or sales department, but works with partners to sell its products and technologies. Dyadic is also interested in forming partnerships with other companies and academic research institutions to develop new technologies and products. Summary Dyadic International Inc is a biotechnology company specializing in the development and manufacturing of biopharmaceutical products, enzymes, and cellulose-containing products. The company has proprietary technologies that can be used in many applications and collaborates with partners and customers to develop new products and technologies. The company's focus is on researching and developing new technologies and applications.

The expected revenue of Dyadic International is 6.82 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Dyadic International is -2.93 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Dyadic International is currently -10.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dyadic International stock.

The price-to-sales ratio (P/S) of Dyadic International is currently 4.55. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dyadic International stock.

The Eulerpool Quality Score for Dyadic International is 3/10.

The ISIN of Dyadic International is US26745T1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Dyadic International is A0JK0A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Dyadic International is DYAI. The ticker symbol is used to trade Dyadic International shares on the stock exchange.

Dyadic International paid dividends every year for the past 0 years.

Dyadic International is assigned to the 'Health' sector.

The dividends of Dyadic International are distributed in USD.

All fundamentals and in-depth analysis of Dyadic International

Our stock analysis for Dyadic International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dyadic International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Dyadic International Stock
Dyadic International Revenue→
Dyadic International Stock
Dyadic International Net Income→
Dyadic International Stock
Dyadic International P/E→
Dyadic International Stock
Dyadic International P/S→
Dyadic International Stock
Dyadic International EBIT→
Dyadic International Stock
Dyadic International Dividend→
Dyadic International Stock
Dyadic International Directors Dealings→
Dyadic International Stock
Dyadic International Stocks→
Dyadic International Stock
Dyadic International Market capitalization→
Dyadic International Stock
Dyadic International Debt→
Dyadic International Stock
Dyadic International Liabilities→
Dyadic International Stock
Dyadic International Equity→
Dyadic International Stock
Dyadic International AAQS→
Dyadic International Stock
Dyadic International Employees→
Dyadic International Stock
Dyadic International ROE→
Dyadic International Stock
Dyadic International ROA→
Dyadic International Stock
Dyadic International ROCE→
Dyadic International Stock
Dyadic International News→
Dyadic International Stock
Dyadic International Analyst Price Targets→

Health Stocks

Dynamic Medical TechnologiesDx & Vx CoDyne TherapeuticsDVxE for L Aim PCLDv Biomed CoEagle PharmaceuticalsDuoGenic StemCellsEagle Veterinary Technology CoDT&CRO CoEarth Science TechDrug Free SolutionAll Stocks A–Z →